RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

The RAPS store will be under maintenance Saturday, 13 June between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > China to Require Registration of all Clinical Trials, Bioequivalence Studies

China to Require Registration of all Clinical Trials, Bioequivalence Studies

Posted 19 September 2013 | By Ansis Helmanis

China's Food and Drug Administration (CFDA) is requiring clinical trial sponsors to register all trials (Phases I, II, III, IV) and bioequivalence testing, according to World Health Organization (WHO) requirements posted online.

The 6 September 2013 bulletin mandates that the required information be posted within one month after pre-registration of the trial, followed by an update within one year.

The trial's approval will be revoked if the registration requirements are not complied with within three years. For approved drugs, the registration must be completed within three months of the date of the notice. 

The website will be managed by CFDA's Center for Drug Evaluation.


CFDA Clinical Trial Registration Requirements

Read all Breaking News from RegLink


Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe